About RHEI

Licensing Strategy

RHEI acquires the licenses for China for proprietary products in the therapeutic areas of oncology, women’s health, dermatology, and infectious diseases. Two historic late stage products in its pipeline target cardiovascular and neurologic conditions. RHEI’s strategy is to in-license marketed products or products in late stages of development which offer distinctive advantages in the market place. The products RHEI currently holds in its portfolio all have the specific characteristic of having a long and proven medical track record outside of China, combined with a unique clinical benefit to the patient, mostly in the form of an optimized formulation, compared to existing competitive products. The combination of proven medical advantages with enhanced clinical benefits minimizes the risk of non-registration on the Chinese market and at the same time offers a unique selling proposition. RHEI’s comprehensive capabilities and licensing strategy provide pharmaceutical and biotechnology company partners with the following benefits:

• Incremental revenue with minimal effort and little to no investment.
• Experienced China team with proven regulatory and commercialization success.
• Privileged access to resources within China.
• Privileged access to top GCP clinical development centers with commitment to GCP quality data.
• National sales coverage offering penetration into large volume tier III hospitals with expansion to mid-tier hospitals.
• The creation of multi-layer drug protection strategy through patents and manufacturing related exclusivity.